Compulsive Sexual Behavior Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled Study of Naltrexone in Compulsive Sexual Behavior
The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in compulsive sexual behavior. Twenty subjects with DSM-IV compulsive sexual behavior will receive 8 weeks of naltrexone or placebo. The hypothesis to be tested is that naltrexone will be effective in reducing the urges to act out sexually in patients with compulsive sexual behavior. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Status | Completed |
Enrollment | 7 |
Est. completion date | June 2010 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. men and women age 21-75; 2. current diagnosis of compulsive sexual behavior Exclusion Criteria: 1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination; 2. history of seizures; 3. myocardial infarction within 6 months; 4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential; 5. clinically significant suicidality; 6. current or recent (past 1 month) DSM-IV substance abuse or dependence; 7. illegal substance within 2 weeks of study initiation; 8. initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline; 9. initiation of a psychotropic medication within 2 months prior to study inclusion; 10. previous treatment with naltrexone; and 11. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota - Clinical and Translational Science Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Yale Brown Obsessive Compulsive Scale Modified for Compulsive Sexual Behavior (YBOCS) | The YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). | Assessed at each visit (every two weeks) until participation in the study was done (Week 8) | No |
Secondary | Clinical Global Impression Scale - Severity | The CGI consists of two reliable and valid 7-item Likert scales used to assess severity in clinical symptoms. The scale ranges from 1 = "very much improved" to 7 = "very much worse." The CGI severity scale was used at each visit and ranges from 1 = "not ill at all" to 7 = "among the most extremely ill." | Assessed at each visit (every two weeks) until participation in the study was done (Week 8) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06408545 -
Acceptance and Commitment Therapy for Problematic Chemsex
|
N/A | |
Not yet recruiting |
NCT06406296 -
Effectiveness of ACT for Problematic Chemsex
|
N/A | |
Enrolling by invitation |
NCT04634175 -
Mind-body Intervention for Compulsive Sexual Behavior Disorder
|
N/A | |
Completed |
NCT05572372 -
Effects of an ACT-based Psychological Treatment in Patients With Hypersexuality
|
N/A | |
Completed |
NCT02300051 -
Intervention Study for Individuals With Compulsive Sexual Behavior
|
N/A | |
Completed |
NCT03495414 -
Neurobiological Underpinnings to Hypersexual Disorder
|